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In a given year, Americans are likely to see about 30 hours of  advertisements for prescription medications on television 
(Brownfield, Bernhardt, Phan, Williams, & Parker, 2004). Known as 
direct-to-consumer advertising (DTCA), this practice refers to the 
promotion of  prescription medications through media including 
television, magazines, newspapers, radio, and online sources 
targeting consumers- not just medical professionals (Food and 
Drug Administration, 2013). Since 1997, the U.S. has been the only 
other country besides New Zealand that allows the practice due to 
a change in policy by the FDA (Callaghan, Laraway, Snycerski, & 
McGee, 2013).
Defining the Problem
 DTCA has been a widely debated issue with strong 
arguments on both sides. Proponents claim that DTCA strengthens 
relationships between doctors and patients by creating more 
informed patients who are engaged with their medical care, increasing 
acceptance of  medication use, educating patients how to advocate 
for themselves, and informing the public about conditions (Donohue 
& Berndt, 2004, Holmer, 2002; Kelly, 2004; Myers, Royne, & Dietz, 
2011). On the other side of  the debate, there is the argument that such 
advertisements use emotional appeals to convince otherwise healthy 
people that they are sick and need treatment through medications 
that they do not need, and that could cause harm (Arney & Menjivar, 
2014; Doran & Hogue, 2014; Frosch, Krueger, Hornick, Cronholm, 
& Barg, 2007; Lemanksi & Villegas, 2015; Wolinsky, 2005).
 There are risks and benefits to every policy, much like the 
risks and benefits to taking a medication. In the case of  DTCA, 
doctors, patients, pharmaceutical companies, and the FDA all have 
something at stake. This health policy brief  presents the history of  
DTCA, why it came about when it did, and reviews the research 
supporting both sides of  the debate. Finally, alternative approaches 
to the practice are considered.
Historical Background 
 Although policy changes to the Food, Drug, and Cosmetics 
Act (FDCA) in 1997 were the driving force behind DTCA becoming 
as widespread as it is today, efforts to regulate pharmaceuticals 
began in the early 1900s. In 1906, the government became more 
involved in the regulation of  food and drugs due to safety concerns 
for consumers when they implemented the Pure Food and Drug 
Act. The law put in place labeling regulations to inform consumers 
about ingredients in medications but did not evaluate their safety or 
effectiveness (Donohue, 2006; FDA, 2015; Gellad & Lyles, 2007). 
It also did not stop manufacturers from making statements that 
exaggerated the effectiveness, claiming it treated a condition when it 
did not or stopping the use of  potentially dangerous chemicals such 
as cocaine, alcohol, or even poison in the drugs (Donohue, 2006; 
Mogull, 2008).
 Finding this approach to be insufficient in protecting 
consumers, the Food, Drug, and Cosmetic Act (FDCA) of  1938 
was passed, created the FDA, and defined its role in the process 
of  pharmaceutical advertising. Its mission, as it still is today, was to 
pre-approve medications before they were sold in order to protect 
consumers and expand labeling regulations to include instructions 
for use. The 1938 law only focused on medication safety.  However, 
in 1962, the act was amended, adding a requirement that medications 
also be proven effective before receiving approval for marketing 
(Donohue, 2006; FDA, 2013; FDA, 2015; Gellad & Lyles, 2007; 
Mogull, 2008).
 The laws described above were prompted by the practice 
of  self-diagnosis/self-medication by consumers and false therapeutic 
claims being made by manufacturers. To obtain a drug from a 
pharmacy, even one with potentially dangerous ingredients or side 
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effects, a person did not need a doctor to write a prescription. The 
FDCA addressed these concerns by requiring prescriptions for 
certain medications written by doctors to limit access, a regulation 
expanded to include more medications in 1951. Another reason for 
this change was pressure from the American Medical Association 
that had a strong interest in shifting to doctors being the exclusive 
gatekeepers to medication. This was in part due to their concern that 
self-diagnosis could diminish the power dynamic between doctors 
and patients (Donohue, 2006; FDA, 2015; Mogull, 2008).
 After the 1938 law took effect, there was a move away 
from self-diagnosis and more control over healthcare given to 
doctors. Pharmaceutical companies also moved their advertising 
focus exclusively to medical professionals. As a result of  this 
shift, physicians not only prescribed medications, they also were 
responsible for informing patients of  the risks associated with the 
medication. Some claim that this practice went too far and interfered 
with patients’ rights in healthcare. Concerns about self-diagnosis, 
self-medication, and the extent of  a doctor’s role in medical decision 
making have been an underlying point in the debate over DTCA that 
continues today (Donohue, 2006; Mogull, 2008).
Evolving Views
 From the time the FDCA was passed, concern surrounding 
the amount of  information, and the means by which it was 
delivered has been debated vehemently. After FDCA, doctors had 
primary control over information being communicated to patients. 
Concerns that patients were not receiving adequate risk information 
led consumer groups to push for alternative ways to access the 
information that at the time was provided only to doctors (Donohue, 
2006; Gellad & Lyles, 2007). 
 One approach proposed by the FDA was to require patient 
package inserts (PPIs) with medications to educate patients about 
the drug’s risks. However, the pharmaceutical companies opposed 
this approach due to high costs of  production of  the inserts. They 
also had concern about devaluing the doctor-patient relationship. 
In response, the FDA relaxed the requirements for PPIs and 
instead, only required inserts for specific drug classes rather than all 
medications (Donohue, 2006).
 Conversation surrounding PPIs, mainly the push by 
consumer groups for distribution of  information, led to a change 
in pharmaceutical companies’ thinking regarding DTCA. However, 
during the 1960s and 1970s, DTCA continued to focus exclusively on 
advertising to physicians due to strict guidelines. In all advertisements, 
they were required to communicate all risks and contraindications to 
consumers. Pharmaceutical companies felt burdened by the amount 
of  information the FDA required as they felt it took away from the 
promotional nature (Donohue, 2006; Gellad & Lyles, 2007; Mogull, 
2008). 
 In the early 1980s, the first DTCA was put out to the public. 
After a temporary moratorium put in place by the FDA that ended 
in 1985, the FDA announced that all pharmaceutical advertisements 
to consumers had to include the same information that would be 
communicated to doctors. This essentially restricted DTCA to print 
form, as it was the only form of  media where all information required 
by the FDA could be included (Donohue, 2006; Mogull, 2008). 
 Between the initial advertisements in the early 1980s and 
the current guidelines that were issued in 1997, usage and spending 
on DTCA grew. Then in 1997, the FDA released new guidelines that 
took effect in 1999, allowing pharmaceutical companies to advertise 
through broadcast media for the first time by loosening requirements 
of  communicating risks to consumers. The guidelines put forth in 
1997, which will be outlined in further detail below, remain essentially 
the same today with some changes made in 2006 (Donohue, 2006; 
FDA, 2013; FDA, 2015b; Gellad & Lyles, 2007; Mogull, 2008).
The Impact of  Consumerism on DTCA
 During the 1980s and early 1990s, consumer groups 
became more vocal about the need for awareness about conditions/
diseases and risks associated with treatment. This is known as the 
beginning of  the patient and consumer rights movements. The 
consumer and patient movements called for more transparency in 
the communication of  information and a strengthening of  the role 
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of  individuals in their care. In the case of  health care, this meant 
a push for shared decision-making between the doctor and patient. 
This was in part due to the influence of  the aging baby boomers who 
were more autonomous than previous generations (Donohue, 2006; 
FDA, 2015; FDA, 2015b). 
 PPIs were a first attempt at bridging this gap. However, 
they only informed the person of  potential risks after the decision 
to prescribe was made (presumably based on information by the 
doctor). DTCA, on the other hand, empowered consumers by 
providing knowledge prior to meeting with their doctor, allowing 
for a more informed discussion between the two (Donohue, 
2006). Consumerism and autonomy in medical decision-making 
undoubtedly played a major role in the development of  DTCA as it 
is today.
The Current Law
 In 1997, the FDA issued guidelines for pharmaceutical 
companies that opened the doors for DTCA through broadcast 
media. These guidelines outline what information must be included 
in all promotional materials and advertisements. These guidelines 
differed from past guidelines in that they do not require all risk 
information to be included. Instead, they must make reference to 
alternative sources of  information such as doctors or toll-free phone 
numbers (FDA, 2013; FDA, 2015c; Gellad & Lyles, 2007). According 
to the FDA (2013), three categories of  advertisement are used in 
DTCA: reminder, help-seeking, and product claim. 
 Reminder advertisements are meant to increase brand 
recognition and contain only the product’s name. Regulations state 
that advertisements cannot include any information about the 
purpose of  the drug or its effectiveness.  The advertisement assumes 
that the audience is already aware of  this information. 
 Help-seeking advertisements present information about 
a condition and recommend contacting a medical professional. 
They do not include names of  medications, are not considered an 
advertisement for the medication, and fall under the Federal Trade 
Commission. However, if  there is only one medication to treat a 
condition, these advertisements cannot be used (FDA, 2013; FDA, 
2015a; Gellad & Lyles, 2007). 
 The final category, product claim advertisements, 
identifies a specific drug and explains the risks and benefits. These 
advertisements are overseen by the FDA and are required to present 
specific information. This information includes the name of  the 
drug, FDA approved uses, and major risks of  the medication. For 
television and radio advertisements, all risks must be included, or 
a list of  alternative sources of  information regarding risks (such as 
doctors, website, print advertisement, or toll-free number) must be 
communicated. For print advertisements, more information, known 
as the brief  summary, is required, which must include an extensive 
list of  side effects, populations who should not take the drug, and 
when medications should not be taken (FDA, 2015a). 
 The FDA monitors all advertisements for accuracy and 
encourages the use of  plain language that non-medical people can 
understand. Although the FDA encourages companies to submit 
their advertisements for review prior to distribution, companies are 
not required to have their materials prescreened; instead, the FDA 
responds, after distribution of  the advertisement, to complaints of  
false or misleading statements made in the material (FDA, 2013; 
FDA, 2015a). 
 Examples of  misleading information can include claiming 
a drug is more effective than demonstrated in trials, omitting 
information about side effects or risks, comparing drugs without 
evidence, claiming that a drug treats a condition that has not been 
confirmed by the FDA, and/or giving an unbalanced weighting to 
the benefits over the risks. If  a company is found to be in violation 
of  the FDA’s policy, the FDA sends a violation letter, asking the 
company to discontinue the advertisement. If  the FDA feels that the 
misinformation presented was harmful to consumers, the FDA can 
require corrective advertising to be distributed to negate the effects. 
Serious violations are rare, but can result in product seizures and 
criminal charges (FDA, 2013).
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Analysis and Evaluation
 Positive outcomes. Proponents of  DTCA argue that 
expanding DTCA would lead to better-informed consumers, who 
would be more engaged in their healthcare. Results of  a survey of  
physicians by the FDA in 2004 found that physicians overall felt that 
patients were in fact more involved in their healthcare and asked 
thoughtful questions regarding treatment options as the result of  
DTCA (FDA, 2015c). For example, Myers et al. (2011) found that 
men who had viewed DTCA for Viagra were more likely to engage in 
a conversation with their doctor about erectile dysfunction. McRoy, 
Weech-Maldonado, and Kilgore (2014) found that more spending on 
DTCA was correlated with fewer emergency room visits for asthma 
among Medicaid-enrolled children. 
 Negative outcomes. As opponents predicted, many 
doctors feel that patients are overly confident in the benefits of  
a drug and are not as informed about the risks associated with 
medications as is necessary to make an informed decision (FDA, 
2015c). A survey found that 78% of  doctors felt their patients were 
able to comprehend the benefits of  the advertised drug, but only 
40% believed that their patients had a clear understanding of  the risks 
associated with a particular medication.  Also of  concern was the 
finding that doctors felt some pressure to prescribe a drug when it was 
requested, even if  they did not feel it was appropriate (FDA, 2015a; 
FDA, 2015c). Research by Mintzes et al. (2003) found that, compared 
to Canadians who have little exposure to DTCA, Americans made 
more requests for advertised drugs and were 17 times more likely to 
receive that drug from their doctor, supporting the doctors’ claims. 
FDA (2013) policy does not require advertisements to go through 
a pre-screening process before distribution, creating the possibility 
for mislabeling and inaccurate information being disseminated to 
the public. In these instances, corrective action including corrective 
advertising can be required of  the company. However, Aikin et al. 
(2015) conducted a study that indicated that corrective advertising 
only works in cases where the effectiveness is overstated, not when 
risk is not communicated, causing potential harm to consumers. 
 Cost and profits. In 2014, Americans spent 300 billion 
dollars on prescription medications compared to about 100 billion in 
1997 (IMS Health, 2015). While research has not shown DTCA to be 
directly linked to the rise in prescription drug use or cost, a correlation 
can be observed. The number of  new drugs on the market does have 
an impact on the amount spent by consumers (IMS Health, 2015), 
and according to Gellad and Lyles (2007), new drugs tend to be the 
most heavily advertised. This could serve as a possible link between 
DTCA and prescription drug spending. Studies have demonstrated 
that DTCA has resulted in increasing conversations about diseases 
that previously were not discussed or considered. Diseases that were 
not previously being treated, and now are, such as adult attention 
deficit disorder, social phobia, depression, erectile dysfunction, and 
irritable bowel syndrome, could be a driver in rising prescription drug 
spending. More research would be needed (Arney, & Menjivar, 2014; 
Conrad & Leiter, 2004; Myers et al., 2011; Wolinksy, 2005).
 DTCA is a source of  large profits for pharmaceutical 
companies. In the year 2000, pharmaceutical companies made $4.20 
for every dollar they spent on advertising (Kaiser Family Foundation, 
2003). While less money is spent on DTCA than advertising directly to 
medical providers through medical journals, in 2011, pharmaceutical 
companies spent 3.9 billion dollars on advertising, representing a 
significant increase since the introduction of  the law in 1997, when 
200 million was spent (Encinosa, Myershoefer, Zuvekas, & Du, 2014; 
IMS Health, 2012). 
Opposing Views
 Proponents and opponents of  DTCA have the same goal 
in mind: to protect the public from medications that could potentially 
cause them harm. Proponents generally feel that the more education 
and autonomy regarding a drug the better, and that DTCA does just 
that. While opponents do not necessarily disagree with knowledge 
being key, they express concern that the DTCA provides knowledge 
through inappropriate avenues and creates a medicalized society. The 
two sides have strong arguments, both of  which should be taken 
under consideration. 
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The Benefits of  DTCA
 The benefits of  DTCA focus on the doctor-patient 
relationship that is strengthened by providing education to the 
consumer. According to an FDA (2015c) survey, doctors feel that 
patients had more thoughtful questions and were able to more 
effectively communicate during appointments. Dens, Eagle, and 
Pelsmacker (2008) studied differences in attitude towards DTCA 
and behavior between people in New Zealand (where DTCA is 
legal) and Belgium (where it is not). They found that people in New 
Zealand were more likely to seek information about risk than those 
in Belgium as a result of  DTCA. Dens et al. (2008) and Donohue and 
Berndt (2004) found that even when patients spoke to their doctor 
about a medication they heard about through DTCA, they did not 
necessarily receive that medication. Donohue and Berndt also found 
that advertising directly to doctors, a practice known as detailing, had 
more substantial effect on which medication was prescribed. 
 Many critics of  DTCA have expressed concerns that DTCA 
will lead to drug seeking by people who do not need the medication. 
In an experiment by Callaghan et al. (2013), the researchers found 
that those who scored high on a depression scale were more likely 
to report a desire to request Cymbalta than those who scored low. In 
other words, there was no inappropriate drug seeking, as participants 
who were most in the need of  the medication were the most likely 
to request it. This study also did not support critics’ concerns that 
viewing DTCA would lead to an increased desire to seek the drug. 
In fact, this study found the opposite- those who viewed DTCA for 
Cymbalta were less likely to report a desire to request the drug from 
their doctor. The authors link this directly to the person’s knowledge 
of  side effects and contraindications as a result of  viewing the 
advertisement.
 Kelly (2004) and Holmer (2002) point out that drug therapy 
is effective and can help to prevent the need for hospitalization, 
thereby lowering healthcare costs. Without DTCA, underserved 
populations, who might not otherwise have been aware that they 
had a condition, would have not sought preventative treatment and 
incurred higher costs in the long run (Kelly, 2004; Holmer, 2002; 
Myers et al., 2011). For example, children with asthma who were on 
Medicaid had less emergency room visits when more money was 
spent on DTCA, suggesting that increased viewing leads to better 
health outcomes (McRoy et al., 2014). 
 DTCA also was found to normalize certain conditions, 
such as erectile dysfunction and depression; create dialogues between 
doctors and patients that otherwise would not have happened; and 
create a better quality of  life. Building lines of  communication and 
collaborative relationships between doctors and patients creates more 
motivation to adhere to a medication regiment because the patient 
feels that he/she was involved in the decision (Corrigan, Kosyluk, 
Fokuo, & Park, 2014; Donohue, 2006; Holmer, 2002; Khanfar, Polen, 
& Clauson 2009; Kravitz et al., 2005; Myer et al. 2011).
The Concerns About DTCA
 According to Brownfield et al. (2004), Americans view 
about 30 hours of  DTCA per year. The authors point out that in 
contrast, people can spend as little as 15 minutes with their doctor 
in a given year. Considering how often consumers are hearing 
these messages, it is important that they receive accurate and 
comprehensive information. While the education DTCA provides to 
consumers has benefits, critics point out that it is also important to 
consider that pharmaceutical companies- who profit from the use of  
the drugs – are the ones designing and funding the advertisements. 
Advertisements are meant to sell a product for the company, not to 
altruistically educate the consumer. 
 A content analysis of  DTCA by Frosch et al. (2007) 
supports this notion; they found that advertisements relied mainly on 
making emotional appeals by depicting people who are unable to live 
fulfilling lives without the medications. Lemanski and Villegas (2015) 
found that a predictor of  a person’s attitude towards a drug advertised 
is reliant on multiple considerations including personal experiences 
with the disease and other individual factors. By depicting characters 
in the commercials, who viewers relate to DTCA, this can effectively 
persuade viewers to request the product. Lee, King, and Reid (2015) 
provide evidence of  this as they found that DTCA affects behaviors 
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of  individuals who view them (i.e. requesting medication, using 
medication). Additionally, in a review of  the literature on DTCA, 
Mintzes (2012) found that nine studies published between 2005 
and 2010 supported the notion that DTCA increases demand and 
prescriptions of  medications.
 The use of  emotional appeals provides support to critics 
who claim that DTCA leads to medicalization and disease mongering 
that increases profits for drug companies. In other words, by using 
DTCA, pharmaceutical companies are expanding the market for 
diseases and are creating anxiety for healthy people to believe they 
are sick, or that there is a cure to what was formerly considered an 
innocuous problem. Pharmaceutical companies do this by using a 
number of  techniques including normalization of  the condition, 
promotion identification through emotional appeals, and facilitation 
of  self-diagnosis by providing symptoms checklists (Arney & 
Menjivar 2014; Doran & Hogue, 2014; Wolinsky, 2005).
 Medicalization and disease mongering, resulting in increased 
usage, have potentially dangerous consequences for consumers who 
utilize prescription drugs. The use of  prescription medications 
increased over the course of  10 years. In 2008, 48% of  people versus 
44% in 1999 used one prescription drug in the last month, and 11% 
versus 6% used more than 5 (Centers for Disease Control, 2010). 
Niederdeppe, Byrne, Avery, and Cantor (2013), in a study of  statin 
use for high cholesterol, found that people who were at relatively 
low risk for heart problems were the driving force behind a rise in 
usage; however, high-risk patients were no more likely to use statins 
or be diagnosed with high cholesterol. The authors caution that use 
of  statins in otherwise healthy people can have more negative rather 
than positive effects. The CDC (2010) notes that poly-pharmacology 
puts people at higher risk for interactions and side effects of  
medications. These risks are potentially more harmful than the 
conditions themselves and include decreased medication adherence 
and higher health care costs.
 While pharmaceutical companies are not entirely to blame 
for this process, consumers who ask their doctors for the medication 
and receive a prescription also contribute. The advertisements 
act as a driver for spreading the rhetoric surrounding disease and 
medicalizing life’s problems as is the case with Viagra and erectile 
dysfunction (Myers et al., 2011; Wolinsky, 2005). Myers et al. (2011) 
found that men who had viewed DTCA for Viagra were more likely to 
engage in a conversation with their doctor about erectile dysfunction. 
While some, including the authors, claim this is commendable, it also 
shows how DTCA is creating demand for treatments for diseases 
that previously were considered a normal part of  aging. 
 Viagra represents a “lifestyle” drug: a medication that 
improves quality of  life rather than treating a disease. Without 
DTCA, drugs such as Viagra or Rogaine (for hair loss) may never 
have been discussed with a doctor as erectile dysfunction and hair 
loss formerly considered normal parts of  aging. Normalizing these 
conditions creates the need for medications that otherwise would not 
have existed - the definition of  disease mongering (Corrigan et al., 
2014; Donohue, 2006; Moynihan, Heath, & Henry, 2002; Myer et al. 
2011).
Looking Towards the Future 
 Throughout its history, arguments promoting DTCA have 
centered on a desire for distribution of  accurate information that 
provides education to consumers who are taking the drug. Research 
has shown that conversations between doctors and patients have 
increased as a result of  DTCA, and more people are being treated 
for diseases then they would have been aware of  or treated for 
previously. Doctors also report that patients who viewed DTCA 
were more engaged and informed (Corrigan et al., 2014; Donohue, 
2006; FDA, 2015c; Gellad & Lyles, 2007; Holmer, 2002; Kelly, 2004; 
Khanfar et al., 2009; Kravitz et al., 2005; Mogull, 2008; Myers et al., 
2011)
 While DTCA is one approach that has had some success 
in bridging the knowledge gap between patients and doctors with 
regards to risks and benefits of  medications, such education is a by-
product (Corrigan et al., 2014; Holmer, 2002; Khanfar et al., 2009; 
Kelly, 2004; Kravitz et al., 2005; Myer et al. 2011). Pharmaceutical 
companies fund DTCA and use emotional appeals to persuade 
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viewers that they need a medication, thereby increasing sales and 
creating profits (Arney, & Menjivar, 2014; Doran & Hogue, 2014; 
Frosch et al., 2007; Lemanski & Villegas, 2015; Wolinsky, 2005). 
Also of  concern is that research has shown that when consumers 
are educated about the risks, they are actually less likely to request 
the medication (Callaghan et al., 2013). This would be a positive 
finding if  other research did not demonstrate that consumers are 
far more educated about the benefits of  a medication than they are 
about the associated risks (FDA, 2015c). Given this information, it is 
clear that pharmaceutical companies are profiting from people being 
under-educated about risks and alternative options of  medications 
presented.
An Alternative Approach 
 In light of  the above evidence, DTCA appears to not be 
the best means through which to effectively communicate the risks 
and benefits of  medications; however, consumers do need access to 
information regarding conditions, medications, and therapies for a 
condition. It is possible that the issue lies in the fact that DTCA 
focuses on one specific drug rather than educating viewers about 
multiple options to treat a specific condition. 
 An alternative to modern DTCA may involve going back 
to the roots of  DTCA. Donohue (2006) points out that disease-
specific advocacy groups were a large part of  the campaign for 
DTCA. Another approach may be to turn the task of  disseminating 
information over to these advocacy groups that can promote all 
treatment options rather than just one medication. For instance, a 
group that advocates for increased awareness of  depression may 
provide information about alternative treatments such as therapy 
and lifestyle changes, in addition to multiple antidepressants that are 
available and the associated risks and benefits through various modes 
of  advertisement. 
 Given that pharmaceutical companies make large profits 
from DTCA, it is likely that policy change will be difficult (IMS, 
2012; IMS 2015; KFF, 2003).  However, if  the FDA is committed to 
educating the public about the risks and benefits of  medications, they 
will see that a change is necessary.
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